Who are DEM BioPharma's investors?

DEM BioPharma's investors include Alta Partners, Astellas Venture Management LLC, DC Investment Partners, Longwood Fund, Pfizer Venture Investments, UTokyo Innovation Platform Co. Ltd., Insight Partners, Pfizer Ventures.

Where is DEM BioPharma headquartered?

DEM BioPharma is headquartered in Cambridge, US.

DEM BioPharma

Cambridge, US · 8 known investors

Find your way into DEM BioPharma

188 people in our graph share verified history with the DEM BioPharma team — schools, employers, funds. One of them is your warm intro.

Glenn Shortunlockedknows John McCabe · together at Flex Pharma (overlapped)

×2knows the team · via Oncorus

×5knows the team · via DEM Biopharma, Inc.

×4knows the team · via ARIAD Pharmaceuticals, Inc.

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research. The company applies discovery approaches based on academic work in genetics and cancer biology.

Biotech Healthtech

Founders & leadership

Nenad GrmusaChief Executive Officer

John McCabe Chief Financial and Operating OfficerJohn McCabe is Chief Financial and Operating Officer of DEM BioPharma, a biotechnology company developing cancer therapies. He has spent over 20 years in life sciences, consulting, and technology roles, with experience in private company financing, biotech IPOs, and operations management across finance, accounting, and startup functions.

Investors · 8

Alta Partnerslisted by Alta PartnersJackson · $1M – $12M

How we know: Alta Partners's portfolio page · funding news · Not right? Tell us

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

How we know: Astellas Venture Management LLC's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

DC Investment Partnerslisted by DC Investment PartnersMcLean · $10M

How we know: DC Investment Partners's portfolio page · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

UTokyo Innovation Platform Co. Ltd.listed by UTokyo Innovation Platform Co. Ltd.Tokyo

How we know: UTokyo Innovation Platform Co. Ltd.'s portfolio page · funding news · Not right? Tell us

Insight PartnersreportedNew York · $120M – $350M

How we know: funding news · Not right? Tell us

Pfizer Venturesreported

How we know: funding news · Not right? Tell us

In the news

DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO - BioSpacebiospace.com · Sep 2022

Frequently asked questions

What does DEM BioPharma do?: DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research. The company applies discovery approaches based on academic work in genetics and cancer biology.
Who are DEM BioPharma's investors?: DEM BioPharma's investors include Alta Partners, Astellas Venture Management LLC, DC Investment Partners, Longwood Fund, Pfizer Venture Investments, UTokyo Innovation Platform Co. Ltd., Insight Partners, Pfizer Ventures.
Where is DEM BioPharma headquartered?: DEM BioPharma is headquartered in Cambridge, US.